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Abstract 
Introduction Carbapenem-resistant Klebsiella pneumoniae is an emerging healthcare-associated 
pathogen with dynamic molecular epidemiology. This study presents a retrospective analysis of the 
distribution and antibiotic resistance patterns of ertapenem-resistant ESBL-producing K. pneumoniae 
strains recovered during an outbreak from 2012 to 2014 in a Croatian University hospital. 
Methods We aimed to estimate genetic relatedness of clinical isolates and underlying mechanisms 
that conferred the ertapenem-resistant phenotype. 
Results Expression analysis of genes involved in the antibiotic resistance showed reduced expression 
of major non-selective porin channel OmpK35. Reduced expression of OmpK36 porin channel in 
isolates resistant to at least one more carbapenem, apart from the ertapenem, was found to a lesser 
degree. Pulsed-field gel electrophoresis analysis of genomic DNA revealed that almost all isolates 
belonged to the same genetic clone. 
Conclusions Caution regarding ertapenem-resistant, carbapenemase-negative porin-deficient mutants 
of K. pneumoniae is required as they are widespread, and under selective pressure this could result in a 
local clonal outbreak. 
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Introduction 
Klebsiella pneumoniae is a member of 
Enterobacterales order, and is commonly 
recognized as nosocomial pathogen that can 
cause various infectious syndromes. In humans, 
this bacterium is commonly found in the 
intestinal tract and fecal carriage rates may 
increase threefold during hospitalization. 
Selective pressure of antibiotics in the hospital 
setting gives rise to the evolvement of multiple 
genetic resistance mechanisms. Prolonged 
colonization with antibiotic-resistant K. 
1pneumoniae is common, especially in bedridden 
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patients.1 Quarter-century after the first 
descriptions of extended-spectrum beta-lactamase 
(ESBL)-producing K. pneumoniae in Croatian 
hospitals, more than 40 percent of clinical 
Klebsiella isolates from our hospital are ESBL-
producers.2,3 Carbapenems are the treatment of 
choice for the infections caused by ESBL-
producing organisms. In contrast to the Group 2 
carbapenems (imipenem/ meropenem/ 
doripenem) frequently used for invasive 
infections, ertapenem is more frequently used in 
lower-risk patients without severe sepsis because it 
has no activity against non-fermenting bacteria.  
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However, the emergence of highly 
transmissible carbapenem-resistant (CR) isolates 
narrows the therapeutic choice and therefore 
poses a substantial threat to the hospital 
medicine. Different mechanisms are responsible 
for carbapenem resistance in K. pneumoniae: (i) 
production of carbapenemases and (ii) 
hyperproduction of ESBL or AmpC enzymes 
combined with the major outer membrane 
proteins (OMPs) porin loss or upregulated efflux 
pump.4 K. pneumoniae with reduced susceptibility 
to one or more carbapenems emerged 
sporadically in different geographic regions in 
Croatia in the last two decades. The first CR 
NDM-1 carbapenemase-producing K. pneumoniae 
was isolated in 2008,5 followed by KPC6 and 
OXA-487 carbapenemase-producing bacteria in 
2012, the latter of which disseminated rapidly 
throughout the country. Although CR K. 
pneumoniae has a high potential to cause 
outbreaks in healthcare settings, reports on the 
incidence of ertapenem resistance in K. 
pneumoniae unrelated to the production of 
carbapenemases are limited. 
Porin modification is an important bacterial 
strategy that confines the diffusion of the 
antibiotic into the cell. Mutation of non-selective 
porin channels OmpK35 and OmpK36, which 
are responsible for a remarkably rapid influx of β-
lactams in the wild-type K. pneumoniae isolate, 
have been implicated in reduced susceptibility to 
carbapenems.8 We documented an outbreak of 
an ESBL-producing ertapenem-resistant K. 
pneumoniae strain in the Clinical Hospital Center 
Rijeka that occurred at the beginning of 2012 
and lasted until the end of 2014. Hence, with 
growing prevalence of ESBL-producing K. 
pneumoniae strains and the urgent need for 
optional antibiotic therapies, we aimed to analyze 
the epidemiological and microbiological 
characteristics of the outbreak. We explored the 
genetic relatedness of selected ertapenem-resistant 
clinical isolates and the underlying mechanisms 
that conferred the CR phenotype – the 
expression of genes encoding a component of the 
AcrAB-TolC efflux system and genes encoding 




A retrospective study was performed to 
identify ertapenem-resistant ESBL-producing 
Klebsiella pneumoniae isolates from various clinical 
samples collected from patients hospitalized in 
Clinical Hospital Centre Rijeka, Croatia. This 
institution is a tertiary-level teaching hospital 
situated in three geographically distinct locations. 
It is the major healthcare facility in its region, 
with 1069 acute care beds and outpatient clinic, 
and it serves a population of approximately 
300,000 inhabitants mostly from Western 
(Costal) Croatia. It has 18 clinics (Anesthesiology 
and Intensive Care, Dermatology, Surgery, 
Neurosurgery, Internal Medicine, Infectious 
Diseases, Pediatrics, Gynecology, Oncology, 
Neurology, etc.) and 12 clinical institutes.  
The Ethics Committee of the Clinical 
Hospital Centre Rijeka approved this study and 
waived the need for informed consent. 
Routine susceptibility testing was carried out 
using the disk diffusion method as a part of 
routine laboratory practice. Minimum inhibitory 
concentration assays of selected antibiotics, 
molecular analyses and pulsed-field gel 




A total of 74 ertapenem-non-susceptible K. 
pneumoniae isolates collected from January 2012 
to December 2014 were the subject of this 
retrospective study. All isolates non-susceptible to 
ertapenem (MIC>0.5) with confirmed ESBL-
producing phenotypes were collected as part of 
the routine hospital laboratory procedure and 
were not specially isolated for this study. Isolates 
were obtained from both clinical and active 
surveillance samples of patients hospitalized in 
different hospital wards. Duplicate isolates (the 
same species from the same patient) were 
excluded. Bacteria were stored at -70°C in MAST 
CRYOBANK™ cryogenic vials (MAST 
Diagnostica, Germany). The identification of K. 
pneumoniae complex was performed using the 
VITEK 2 system (bioMérieux, France). In this 
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survey, we did not differentiate between 
colonizing and infecting isolates.  
 
Antimicrobial susceptibility testing (AST) 
Isolates were cultured at 37°C for 24 h on 
Mueller-Hinton agar (BD Difco, France), and 
inoculates were prepared in Mueller-Hinton 
broth (MHB) (BD Difco) at a density adjusted to 
a 0.5 MacFarland turbidity standard. AST was 
performed and interpreted according to 
EUCAST Standard.9 ESBL production was 
screened by phenotypic disc diffusion methods 
(double disk synergy assays) while AmpC beta-
lactamases were tested using inhibitor-based 
method (cloxacillin with cefoxitin and 
phenylboronic acid with cefoxitin). The MIC of 
the antibiotics – ertapenem, doripenem, 
imipenem, meropenem, ciprofloxacin, 
cefotaxime, ceftazidime, gentamicin, amikacin, 
tigecycline and colistin was determined using E-
test according to the manufacturer's instructions 
(AB Biodisk, Sweden). MIC50 and MIC90 levels 
were defined as the lowest concentration of the 
antibiotic at which 50% and 90% of the isolates 
were inhibited, respectively. ESBL production 
was confirmed by cefotaxime/cefotaxime-
clavulanic acid and ceftazidime/ceftazidime-
clavulanic acid ESBL strips (bioMérieux) on MH 
agar. K. pneumoniae ATCC 700603 was used as 
quality control isolate for ESBL production. For 
detection of the major carbapenemases the 
Modified Hodge Test (MHT) and Carba NP Test 
were performed on isolates grown on MH agar 
plates as previously described.10 K. pneumoniae 
ATCC BAA-1705 was used as positive control for 
MHT.  
 
Molecular detection of carbapenemase 
resistance genes 
A full 10-µL inoculation loop with a bacterial 
suspension equivalent to 0.5 McFarland standard 
was added into the sample reagent. After 
homogenization 1.7 mL were subsequently 
transferred into the cartridge and commercial 
Xpert® Carba-R multiplex real-time PCR assay 
(Cepheid, USA) designed for the qualitative 
detection of five carbapenemase genes (blaKPC, 
blaNDM, blaVIM, blaOXA-48, and blaIMP-1) was carried 
on the GeneXpert System – the molecular testing 
platform (Cepheid). 
 
mRNA expression level analysis 
Relative expression levels of the acrA and tolC 
genes coding for the AcrAB-TolC efflux pumps 
proteins, and ompK35 and ompK36 genes coding 
for the outer membrane proteins was analyzed 
using reverse transcription-quantitative PCR (RT-
qPCR) in: (i) isolates resistant to tigecycline, (ii) 
isolates resistant to ertapenem plus one of the 
other carbapenems, (iii) isolates resistant only to 
ertapenem and (iiii) susceptible control isolates. 
We have compared the gene expression levels of 
acrA, tolC, ompK35 and ompK36 genes between 
several groups of isolates. The variables that were 
compared are crossing point (CP) values for the 
qPCR amplification of cDNA of each gene 
between isolates from different groups. The CP 
values for the genes were normalized by the CP 
values for ATPs gene which is used as a reference 
gene in the qPCR. The p values are calculated for 
the comparison of CP values for each gene 
between different groups of isolates. 
The isolates were cultured in brain heart 
infusion (BHI) medium until the suspension 
reached OD600=0.6 (usually 2-3 hours). Total 
RNA was extracted using the High Pure RNA 
Isolation kit (Roche, Germany), and reverse 
transcribed into cDNA using the first-strand 
cDNA Synthesis Kit for RT-PCR (Roche). 
Resulting cDNA was analyzed by RT-qPCR using 
LightCycler FastStart DNA Master SYBR Green I 
(Roche) in the LightCycler 2.0 instrument 
(Roche) to determine if there is a difference in 
the relative expression of acrA gene for efflux 
pump, and tolC for outer membrane component 
of the efflux pump, and two porin channels genes 
– ompK35 and ompK36. The primers used for the 
expression analysis are listed in Table 1.  
Gene expression data was analyzed by 
Relative Expression Software Tool (REST), 
comparing mRNA levels of the genes in the 
clinical isolates with ATPs as the reference gene 
(reaction efficiency 0.9524). Statistical analysis is 
performed in the REST using pair wise fixed  
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reallocation randomization test.13 Results are 
presented as mean values ± standard errors. A p 
value of <0.05 was considered statistically 
significant. 
 
Pulsed-field gel electrophoresis (PFGE)  
K. pneumoniae isolates were genotyped by 
pulsed-field gel electrophoresis of XbaI restricted 
fragments. PFGE was performed as previously 
described with our modifications.14,15 Bacterial 
plugs were sliced in 1-2 mm slices, that were 
digested with 20 U of XbaI restriction 
endonuclease (Fermentas, Lithuania) at 37°C 
overnight, and then transferred to 0.5 × TBE 
buffer, loaded on the comb, and run in 1% 
agarose gel in CHEF-DR III pulsed-field 
electrophoresis system (Bio-Rad, USA) at 6 
V/cm, 120° field angle, 14°C, with initial and 
final switch times between 5 and 30 sec for 22 h. 
Gels were analyzed with GelCompar II software 
(Applied Maths NV, Belgium). PFGE patterns 
were analyzed by BioNumerics GelCompar II 
software. A dendrogram showing clonal 
relationship of the isolates was constructed using 
the unweighted-pair-group method of the 
arithmetic average clustering with the Dice 
similarity coefficient. An optimization of 1.2%, 





The majority of isolates were recovered from 
mid-stream urine (46%, n=34) or catheter 
specimen of urine (CSU) (17%, n=13), followed 
by tracheal aspirate/bronchoalveolar lavage (BAL) 
(17%, n=13), abscess/drainage (6%, 
n=5), blood (4%, n=3) and other 
(8%, n=6). The distribution analysis 
of K. pneumoniae complex isolates 
around clinical wards indicated that 
approximately 30% isolates were 
from the Intensive Care Unit (ICU) 
– mostly isolated from CSU or 
tracheal aspirate/BAL, and just a 
few K. pneumoniae were isolated 
from blood culture). Surgery 
(general surgery, abdominal surgery 
and neurosurgery) accounted for 
approximately 20%, while nephrology accounted 
for 10% of the total isolates (data not shown). 
 
Antimicrobial susceptibility rates 
According to the laboratory´s data, during a 
three-year study period a total of 1884 K. 
pneumoniae complex strains were isolated in our 
laboratory from different clinical samples. The 
overall proportion of ESBL producers among K. 
pneumoniae complex strains was 43.10% (n=812). 
Reduced susceptibility to carbapenems in all K. 
pneumoniae complex isolates in the three-year 
period was noted as stated: 0.10% isolates were 
resistant to imipenem, 0.26% isolates to 
doripenem, 0.32% isolates to meropenem, while 
11.4% isolates were resistant to ertapenem (data 
not shown). The K. pneumoniae complex isolates 
(n=74) with similar pattern of resistance selected 
for this study were subjected to additional MIC 
testing by E-tests. In general, K. pneumoniae 
complex isolates showed multidrug-resistance 
(MDR) to at least one antimicrobial agent from 
three or more antibiotic classes. All isolates were 
resistant to amoxicillin, amoxicillin/clavulanate 
and trimethoprim/sulfamethoxazole (data not 
shown) as well as to broad-spectrum 
cephalosporins (cefotaxime and ceftazidime), 
ciprofloxacin and gentamicin (Table 2).  
In addition to 100% ertapenem resistance, 
3%, 7% and 8% of selected 74 isolates showed 
reduced susceptibility to imipenem, doripenem 
and meropenem, respectively. Resistance to 
tigecycline was noted in 10% of these isolates 
while amikacin and colistin appeared to be the  
Table 1. Primers used in this study 
Gene Primer Sequence Reference 
acrA acrA-F ATGTGACGATAAACCGGCTC 11 
acrA-R CTGGCAGTTCGGTGGTTATT 
tolC tolC-F TTCTCCGCTTCCTTCAGCAG  
tolC-R CTCCCTGAACGTGAATGGCT 
ompK35 ompK35-F GAAGGTTCCCAGACCACAA 11 
ompK35-R ACGGCCATAGTCGAATGAAC 
ompK36 omp36-F GACCAGACCTACATGCGTGTA 12 
ompK36-R GTATTCCCACTGGCCGTAAC 
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most effective drugs as 100% of these isolates 
were susceptible.  
 
Phenotypic and molecular tests for 
carbapenemase detection 
The phenotypic Modified Hodge test and 
Carba NP test were negative in all 74 isolates. No 
carbapenemases genes, blaKPC, blaNDM, blaVIM, 
blaOXA-48, and blaIMP-1, were detected by the 
Cepheid Xpert® Carba-R assay. 
 
Efflux pump expression and porin mutation 
The expression of the acrA and tolC genes 
coding for the AcrAB-TolC efflux pump proteins 
and ompK35 and ompK36 porin-encoding genes, 
was analyzed using RT-qPCR. The expression of 
genes in isolates resistant to tigecycline, isolates 
resistant or intermediate resistant to at least one 
other carbapenem (imipenem, meropenem or 
doripenem), and in the randomly selected six 
ertapenem-resistant isolates was compared to the 
control susceptible wild type K. pneumoniae 
isolates. The results of the comparisons are listed 
in the Table 3.  
The first comparison is between isolates 
resistant to tigecycline and control K. pneumoniae 
isolates susceptible to all antibiotics. We did not 
find any statistically significant difference in the 
expression of acrA and tolC genes between 
tigecycline-resistant isolates and susceptible 
control group. However, we found significantly 
reduced expression of OmpK35 porin in isolates 
resistant to tigecycline compared to the control 
isolates by a mean factor of 0.012 (p=0.003), 
which implies that the expression of OmpK35 
porin in the tigecycline-resistant isolates is around 
80 times lower than in the susceptible control 
samples.  
The second comparison is between isolates 
resistant to more than one carbapenem and 
control K. pneumoniae isolates susceptible to all 
antibiotics. A statistically significant upregulation 
of acrA gene was found in the group of isolates 
resistant or intermediate resistant to at least one 
other carbapenem, apart from ertapenem, 
however the expression was upregulated by a 
mean factor of 1.195 (p=0.023), which implies 
only slight upregulation. We did not find any 
difference in tolC expression. The isolates 
resistant or intermediate resistant to at least one 
other carbapenem, showed significantly (around 
9 times) lower expression of ompK36 porin-
encoding gene, by a mean factor of 0.114 
(p=0.032).  
The third comparison is between isolates 
resistant only to ertapenem and control K. 
pneumoniae isolates susceptible to all antibiotics. 
The comparison of the expression of the 
aforementioned genes was done for the six 
randomly selected isolates resistant only to 
ertapenem. The only difference found was 
strongly reduced expression of the OmpK35 
porin (by a mean factor of 0.015), however it was 
not statistically significant (p=0.075). 












Ertapenem 24 32 18 16-32 100 
Doripenem 0.75 1 0.75 0.5-1 7 
Imipenem 0.19 0.7 0.19 0.19-0.25 3 
Meropenem 1 2 1 1-1.5 8 
Ciprofloxacin 32 32 32 32-32 100 
Cefotaxime 16 16 16 16-16 100 
Ceftazidime 32 32 32 32-32 100 
Gentamicin 16 256 32 16-256 100 
Amikacin 2 4 2 0.5-4 0 
Tigecycline 0.5 1.9 1.5 0.38-1 10 
Colistin 0.125 0.125 0.125 0.125-0.125 0 
IQR – interquartile range. 
MIC50 and MIC90 were defined as MICs at which 50% and 90% of the isolates were inhibited, respectively. 
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The genetic relationships among isolates – 
results of PFGE analysis 
The selected 74 ertapenem-resistant ESBL-
producing K. pneumoniae strains isolated from 
different wards and specimen types were further 
analyzed by PFGE to determine the clonal 
relationship between them. Typeability by PFGE 
was 100%. The phylogenetic tree constructed 
upon PFGE analysis showed that almost all 
clinical samples were clonally related, as 72 out of 
74 (97 %) belonged to the same pulsogroup 
based on >80% similarity criterion, while 67 out 
of 74 (91%) showed >95% genetic similarity 
implying the clonal spread of the single isolate 
throughout the hospital (Figure 1). 
 
Discussion 
K. pneumoniae has a high degree of 
environmental stability – the emergence of high-
risk clones that are very efficient at colonizing the 
human host and responsible for outbreaks in 
hospitals across Europe is worrying. According to 
the European Centre for Disease Prevention and 
Control (ECDC) surveillance report the 
percentage of MDR K. pneumoniae invasive 
isolates with combined resistance to 
fluoroquinolones, third-generation 
cephalosporins and aminoglycosides in Croatian 
hospitals in last few years varied from 23% to 
32%.16 Carbapenems are considered as one of the 
last resort antibiotics used for the treatment of 
nosocomial infections caused by Gram-negative 
bacteria resistant to third-generation of 
cephalosporins.17 Thus, the emergence of 
carbapenem resistance in K. pneumoniae requires 
careful monitoring because of the potential for 
rapid spread of resistance genes through plasmid 
transfer and limited treatment options. Patients 
infected or colonized with CR K. pneumoniae may 
introduce bacteria into the healthcare 
environment leading to dissemination of 
organisms to healthcare personnel and other  
Table 3. Comparison of the relative expression levels of the genes acrA, tolC, ompK35 and ompK36 
involved in the antibiotic resistance between groups of samples 
Comparisona Gene Reaction 
efficiency 
Expression Standard error 95% CI P value 
TIG-R vs. 
control  
acrA 0.9959 1.676  0.976 – 2.460 0.851 – 5.811 0.215  
tolC 1.0 1.187 0.855 – 1.648 0.665 – 2.611 0.469 
ompK35 0.8993 0.012 0.004 – 0.018 0.001 – 0.669 0.003 
DOWNb 
ompK36 0.834 0.931 0.499 – 1.837 0.419 – 2.804 0.850 
CARB-R vs. 
control 
acrA 0.9959 1.195 1.099 – 1.319 1.052 – 1.435 0.023 
UPc 
tolC 1.0 0.868 0.649 – 1.231 0.521 – 1.420 0.440  
ompK35 0.8993 0.296 0.007 – 9.657 0.002 – 10.369 0.580 




acrA 0.9959 0.931 0.621 – 1.513 0.581 – 2.084 0.799 
tolC 1.0 1.313 0.962 – 1.818 0.750 – 2.098 0.224 
ompK35 0.8993 0.015 0.002 – 1.371 0.001 – 17.911 0.075  
ompK36 0.834 0.837 0.337 – 2.275 0.196 – 3.294 0.813 
CI – confidence interval; CARB-R vs. susceptible control – isolates resistant to at least one other carbapenem 
apart from ertapenem compared to the control; ERT-R vs. control – isolates resistant to ertapenem compared to 
the control; TIG-R vs. control – tigecycline-resistant isolates compared to the control isolates. 
aqPCR data were analyzed by Relative Expression Software Tool (REST);13 comparing mRNA levels of the genes in 
the clinical isolates. ATPs was used as the reference gene in all comparisons (reaction efficiency 0.9524). A p value 
of <0.05 was considered statistically significant. 
bompK35 is down-regulated in the sample group (in comparison to the control group) by a mean factor of 0.012. 
cacrA is up-regulated in the sample group (in comparison to the control group) by a mean factor of 1.195.  
d ompK36 is down-regulated in the sample group (in comparison to the control group) by a mean factor of 0.114. 
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patients. Carbapenemase-positive isolates of K. 
pneumoniae have the highest transmissibility to 
spread in hospital environments both within and 
between countries, which have been shown in a 
recent European survey.18 However, a few years 
ago, outbreaks in southern Europe caused by an 
ertapenem-resistant, porin-deficient ESBL-
producing K. pneumoniae raised awareness of 
Figure 1. Dendrogram showing the clonal relationship of K. pneumoniae clinical isolates; black dots 
denote isolates of the same pulsotype (>80 % similarity) 
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emergence and spread of carbapenem resistance 
derived from other mechanisms.19,20  
This study presents a retrospective analysis of 
the distribution and antibiotic resistance patterns 
of ertapenem-resistant ESBL-producing K. 
pneumoniae strains causing clonal outbreak in 
University Hospital Rijeka. According to 
laboratory´s data, resistance to ertapenem in our 
hospital started from 2012 to increase 
remarkably. During the three years period 
reduced susceptibility to ertapenem was noted in 
as many as 11.41% of all K. pneumoniae isolates. 
In order to analyze the mechanisms of resistance 
and genetic relations, retrospective screening was 
performed on a collection of 74 ertapenem-non-
susceptible K. pneumoniae isolates selected during 
three years. The highest number of these isolates 
were from urine (63%), mostly obtained from 
patients hospitalized in the ICU (30%) and 
surgical wards (20%), which is not surprising 
since prolonged hospital stay with indwelling 
urethral catheter is one of the risk factors for 
acquiring nosocomial infection. Phenotypic and 
molecular analyzes ruled out carbapenemases 
production in all isolates. Apart from 
carbapenemase production, K. pneumoniae 
isolates possess several mechanisms to evade the 
activity of carbapenems. Recently, a global survey 
of major porins from ertapenem non-susceptible 
K. pneumoniae isolates lacking carbapenemases 
revealed that porin disruption is a widespread 
phenomenon, and in combination with ESBLs 
and/or AmpC enzymes, likely accounts for the 
elevated ertapenem MICs.21 All studied 
ertapenem-resistant K. pneumoniae strains were 
ESBL producers. According to the laboratory´s 
data, the ESBL-producing strains isolated in our 
laboratory represented 43.10% of the total K. 
pneumoniae isolates. Ertapenem is the most 
sensitive indicator of carbapenem resistance 
affected by carbapenemase production. Our data 
support the finding that ertapenem is also the 
most sensitive carbapenem to permeability 
defects, as the majority (97%, 93% and 92%) of 
the isolates remained susceptible to imipenem, 
doripenem or meropenem, respectively. 
Therefore, ertapenem MICs often increase when 
an organism loses one or more of its porins. The 
presence of ESBL enzymes combined with 
alterations in OmpK35 and OmpK36 porins 
expression can result in ertapenem MICs in the 
intermediate or resistant range, while other 
carbapenems can remain susceptible or have 
raised MICs.21 However, mutations in ompK35 
and ompK36 genes or decrease/loss of the 
OmpK35 or OmpK36 porins expression were 
previously reported as the mechanism of 
resistance to other carbapenems in the 
carbapenemase-negative strains.22,23 In the present 
study, comparing the expression of OmpK35 and 
OmpK36 porins in the isolates resistant or 
intermediate resistant to imipenem, doripenem 
or meropenem, we confirmed that the reduced 
expression of OmpK36 porin channel might be 
involved in the development of resistance to 
those carbapenems. Further, our results show 
that OmpK35 downregulation is probably 
involved in the development of the ertapenem 
resistance since the expression of OmpK35 was 
strongly reduced in the ertapenem-resistant 
isolates compared to the control, even though it 
was not statistically significant.  
We next aimed to investigate the possible 
contribution of AcrAB-TolC efflux pump in 
carbapenem resistance. Interestingly, we found 
slight upregulation of the acrA gene of a mere 
20% in isolates resistant to one or more 
carbapenems, which has not been reported 
previously. The overexpression of an efflux pump 
system in CR isolates might have contributed 
towards carbapenem resistance. Further 
investigation is warranted to clarify the role of 
AcrAB-TolC pump in developing resistance 
against the carbapenem group of antibiotics. 
MDR K. pneumoniae clonal isolate studied 
here remained susceptible to amikacin - 
outstanding among antimicrobials because of its 
high and stable rates of K. pneumoniae 
susceptibility. Although aminoglycosides may be 
used in monotherapy to treat urinary tract 
infections caused by susceptible ESBL-producers, 
the aminoglycoside use in systemic infections 
must be supported by other active therapy.24 
Monotherapy with amikacin is associated with 
increase in multidrug resistance originating from 
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production of aminoglycoside-modifying 
enzymes. 
Beside amikacin, colistin appeared to be the 
most effective drug as all tested isolates were 
susceptible. Since colistin is one of the last-resort 
antibiotics for CR K. pneumoniae infections, its 
resistance, which is continually increasing 
worldwide, represents a treatment challenge. 
Thus, in a recent surveillance of CR K. 
pneumoniae complex from Croatian hospitals 
emerging colistin resistance has been reported.25 
Tigecycline is one of the last resort 
treatments for multidrug-resistant Gram-negative 
bacterial infections. We observed the worrying 
occurrence of tigecycline resistance in isolates 
characterized in the current study. Recent data 
indicate that K. pneumoniae tigecycline resistance 
could be associated with overexpression of AcrAB 
and OqxAB efflux pumps.26,27 In the present 
study we did not detect the overexpression of 
AcrAB-TolC efflux pump in tigecycline-resistant 
K. pneumoniae isolates. Tigecycline resistance, 
which evolved in 10% of ertapenem resistant 
isolates during the course of the monoclonal 
outbreak presented here, could be the result of 
strong reduction of the expression of OmpK35 
porin. However, we cannot rule out other 
mechanisms of the resistance that were not tested 
in our study, since the reduction of OmpK35 was 
also detected in the isolates resistant only to 
ertapenem. 
Resistance to at least one carbapenem, 
frequently to ertapenem, defines the CR 
phenotype. Ertapenem is the most vulnerable 
carbapenem to hydrolysis by β-lactamases and the 
emergence of ertapenem resistance needs to be 
monitored closely. A randomized controlled trial 
found that ertapenem could be efficiently used as 
de-escalation therapy for susceptible ESBL-
producing Enterobacterales, especially for urinary 
tract infections (UTIs).28 Meropenem and 
imipenem often remain moderately active against 
strains with low-level ertapenem resistance. If 
susceptibility of carbapenemase-negative 
Enterobacterales to Group 2 carbapenem is 
retained, treatment with a susceptible 
carbapenem agent as monotherapy is generally 
sufficient. Our study has shown approximately 
the equal susceptibility of K. pneumoniae isolates 
to all Group 2 carbapenem agents. Although 
meropenem showed higher MIC50s (1 μg/mL) in 
comparison to imipenem (0.19 μg/mL), it is 
probably not likely to be clinically significant for 
most susceptible isolates. As there are is clear 
difference in efficacy between meropenem and 
imipenem, the choice to use one over the other 
carbapenem is principally based on toxicity 
profiles in specific patients. Meropenem would 
be preferred option in patients with bacterial 
meningitis, underlying central nervous system 
disease or impaired renal function.29 
Doripenem is a relatively new carbapenem 
and the clinical studies for its use are rare. High 
clinical efficacy and safety of doripenem in the 
treatment of acute bacterial infections is reported 
recently in a systemic review and meta-analysis of 
randomized controlled trials.30 We demonstrated 
here similar in vitro activity of doripenem against 
ertapenem-resistant, ESBL-producing K. 
pneumoniae complex as other Group 2 
carbapenem agents. Accordingly, doripenem 
could be a therapeutic option for the treatment 
of patients with complicated UTI, intra-
abdominal infections and ventilator-associated 
pneumonia caused by ESBL-producing K. 
pneumoniae isolates.  
Group 2 carbapenems are an effective 
treatment against the ertapenem-resistant isolates. 
However, in case of susceptible isolates with 
higher MIC to Group 2 carbapenems a high-dose 
prolonged-infusion regimen is generally 
recommended.31,32 Pharmacokinetic optimization 
of antibiotic therapy increases the likelihood of 
appropriate time above the MIC and the effective 
elimination of pathogens. Several ertapenem-
resistant clinical isolates of K. pneumoniae showed 
Group 2 carbapenem MICs of 2 μg/mL, in 
which case the combination therapy with another 
active drug should be considered. In general, 
aminoglycosides are preferred as a second agent 
added to the extended-infusion carbapenem. The 
use of carbapenems combination therapy is likely 
ineffective for CR isolates with carbapenem 
MICs 4 μg/mL or greater.33 In that case the use 
of a new β-lactam/β-lactamase inhibitor 
combinations (ceftazidime-avibactam, 
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meropenem-vaborbactam, imipenem-relebactam) 
or cefiderocol, a novel siderophore 
cephalosporin, should be considered. 
The limitation of this study is a lack of 
differentiation between colonizing and infecting 
K. pneumoniae isolates. It is important to 
differentiate them and compare their antibiotic 
resistance and molecular typing patterns in future 
studies, as hospitalized patients can become 
infected with the same strain that they carried. 
Characterization of carriage isolates could help 
make treatment decisions in patients that are at 
risk.  
We next analyzed clonal relationships of 
isolates using PFGE method. Molecular typing 
results obtained from the PFGE patterns showed 
indistinguishable patterns, suggesting the 
presence of an epidemic clone circulating within 
the 13 different hospital wards situated in two 
separate hospital buildingslocations. Therefore, 
in the current study multifactorial events resulted 
in carbapenem resistance phenotype, whereupon 
the positive selection imposed by the extensive 
use of antimicrobials (third generation 
cephalosporins and fluoroquinolones) favored 
the expansion of the resistant clone, promoting 
its diffusion within the hospital. Although porin-
deficient mutants may have reduced fitness and 
be less likely to spread in healthcare settings, this 
ertapenem-resistant ESBL-producing clone 
emerged rapidly in our hospital. To prevent 
further hospital-wide dissemination of this MDR 
isolate, infection control measures were taken 
quickly. The outbreak control measures were: 
good clean-up of the hospital environment and 
medical devices, cohorting and screening of 
patients (rectal surveillance cultures performed in 
high-risk wards), prevention of patient transfer to 
other units, and creating awareness in staff about 
hand-washing. Restrictive antimicrobial policy 
consisted of limitation of third generation 
cephalosporins and fluoroquinolones use during 
a nine-month period, as well as education of staff 
about restriction policies and criteria. The 
management of the outbreak by the healthcare 
workers, in collaboration with microbiologists 
and the hospital Infection Control Committee, 
allowed a successful interruption of the “silent” 
dissemination of this clone.  
Conclusions 
Caution regarding ertapenem-resistant, 
carbapenemase-negative porin-deficient mutants 
of K. pneumoniae is required as they are 
widespread, and under selective pressure this 
could result in a local clonal outbreak. Molecular 
typing of bacteria remains an important tool in 
determining the spread of MDR isolates in 
healthcare settings thus providing information 
for successful infection prevention program. 
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